A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy PK, Kinetics and Safety of Aramchol in Nonalcoholic Steatohepatitis (NASH) With Open-Label Part
Latest Information Update: 18 Dec 2024
At a glance
- Drugs Icomidocholic acid (Primary)
- Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
- Focus Registrational; Therapeutic Use
- Acronyms ARMOR
- Sponsors Galmed Research and Development, Ltd.
- 16 Dec 2024 Planned End Date changed from 1 Jun 2027 to 30 Jun 2027.
- 25 Sep 2024 According to a Galmed Pharmaceuticals media release results of the Open-Label part (ARCON ) of its global Phase 3 trial were published in the open access journal Hepatology.
- 25 Sep 2024 Results of the Open-Label part (ARCON ) of its global Phase 3 trial published in the Galmed Pharmaceuticals Media Release